Nimodipine has an inhibitory action on neurotransmitter release from human cerebral arteries.
The effect of the dihydropyridine nimodipine was studied on the resting and K+-evoked release of [3H]acetylcholine (ACh) and [3H]5-hydroxytryptamine (5HT) from postmortem human cerebral arteries. Nimodipine, at a concentration of 30 microM, significantly reduced the K+-evoked release of [3H]ACh from anterior and middle cerebral arteries by 36 and 70%, respectively, and the K+-evoked release of [3H]5HT from basilar and middle cerebral arteries by 55 and 66%, respectively. The mode of action of nimodipine is interpreted in terms of a specific effect on the depolarisation-induced calcium current occurring in neuronal elements present in these preparations but absent from brain.
D000109:Acetylcholine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000328:Adult; D000368:Aged; D002536:Cerebral Arteries / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000494:pharmacology*; D009553:Nimodipine; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology
D009539:Nicotinic Acids; D012702:Serotonin Antagonists; D012701:Serotonin; D009553:Nimodipine; D000109:Acetylcholine